MedTrace Logo

Innovative Biomarkers in de Novo Parkinson's Disease

NCT03940677 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2022-05-12

No results posted yet for this study

Summary

This study aims at identifying potential new and innovative biomarkers in de novo Parkinson's disease patients. New finding will help phenotyping patients since the diagnosis of the disease and potentially also in the preclinical phase.

Conditions

Interventions

PROCEDURE

Brain MRI

3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI

PROCEDURE

TMS-EEG

Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study

BEHAVIORAL

Behavioral and cognitive battery

Emotional, attentional and behavioral assessment using predefine scales and measures

OTHER

Clinical evaluation and clinical scales

Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    collaborator OTHER

  • Grenoble Institut des Neurosciences

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Elena Moro, MD, PhD · CHU Grenoble Alpes

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-25
Primary Completion
2021-12-09
Completion
2021-12-09

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940677 on ClinicalTrials.gov